Company: INTS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001567264-25-000039
Chunk: 58

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 8
Chunk 58
---
 development functions.

General and Administrative Expenses

•Salaries and Benefits Related Costs include employee-related expenses such as salaries and related benefits for employees engaged in fund raising, management, and corporate administration functions.

•Legal Fees include expenses for corporate, patent and trademark fees with outside law firms.

•Audit Fees consist of fees billed for professional services rendered for the audit of our annual financial statements, review of our interim financial statements, comfort and consent letters.

•Consulting services provided by non-employees for general and administrative tasks, includes accounting, tax, human resources, finance, investor relations, board compensation, and internet support.

•Insurance includes directors and officers insurance, workers compensation insurance, product liability insurance, business insurance, employee and cyber liability insurance.

•Other includes facility expenses, office supplies, computer related costs, public relations costs, recruiting costs and conferences.

•Stock-based Compensation relates to stock options granted to our employees and board members and warrants granted to our independent consultants who work in the general and administrative aspects.

Other income and expenses

We earned interest income on our cash balances and investments in U.S. Treasury bills.

17

Results of Operations

The following tables summarize our results of operations for the three months ended March 31, 2025 and 2024 (in thousands):

Three Months Ended March 31,20252024ChangeOperating expenses:Research and development$2,189 $2,815 $(626)General and administrative1,205 1,928 (723)Total operating expenses3,394 4,743 (1,349)Loss from operations(3,394)(4,743)1,349 Interest income15 140 (125)Other income, net32 - 32 Net loss$(3,347)$(4,603)$1,256 

Three Months Ended March 31,20252024ChangeResearch and development expenses:Clinical trial expenses:IT-01 Study (Phase 1/2 Metastatic Cancers)$— $53 $(53)INVINCIBLE-2 Study (Phase 2 Breast)— 103 (103)INVINCIBLE-3 Study (Phase 3 Sarcoma)1,596 1,419 177 INVINCIBLE-4 Study (Phase 2 Breast)63 — 63 Clinical trial expenses1,659 1,575 84 Contract manufacturing24 214 (190)Salaries and benefits related costs329 394 (65)Consult